HN2011000542A - Compuestos de pirrolo- pirimidina como inhibidores de cdk - Google Patents

Compuestos de pirrolo- pirimidina como inhibidores de cdk

Info

Publication number
HN2011000542A
HN2011000542A HN2011000542A HN2011000542A HN2011000542A HN 2011000542 A HN2011000542 A HN 2011000542A HN 2011000542 A HN2011000542 A HN 2011000542A HN 2011000542 A HN2011000542 A HN 2011000542A HN 2011000542 A HN2011000542 A HN 2011000542A
Authority
HN
Honduras
Prior art keywords
pirrolo
pyrimidine compounds
cdk inhibitors
compounds
need
Prior art date
Application number
HN2011000542A
Other languages
English (en)
Spanish (es)
Inventor
Bensong Gilbert
Thomas Brain Christopher
A Brooks Clinton
Stuart Congreve Miles
Dagostin Claudio
He Guo
Hou Ying
Howard Steven
Li Yue
Lu Yipin
Mortenson Paul
Smith Troy
Sung Moo
Woodhead Steven
Wrona Wojciech
Lagu Bharat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011000542(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2011000542A publication Critical patent/HN2011000542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HN2011000542A 2008-08-22 2011-02-22 Compuestos de pirrolo- pirimidina como inhibidores de cdk HN2011000542A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22

Publications (1)

Publication Number Publication Date
HN2011000542A true HN2011000542A (es) 2013-10-17

Family

ID=41171100

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011000542A HN2011000542A (es) 2008-08-22 2011-02-22 Compuestos de pirrolo- pirimidina como inhibidores de cdk

Country Status (48)

Country Link
US (8) US8685980B2 (enExample)
EP (2) EP2331547B1 (enExample)
JP (2) JP5560496B2 (enExample)
KR (2) KR101353857B1 (enExample)
CN (2) CN102186856B (enExample)
AR (2) AR073116A1 (enExample)
AU (1) AU2009284098B2 (enExample)
BR (1) BRPI0917791B1 (enExample)
CA (1) CA2734802C (enExample)
CL (1) CL2011000306A1 (enExample)
CO (1) CO6341561A2 (enExample)
CR (1) CR20110101A (enExample)
CU (1) CU24062B1 (enExample)
CY (2) CY1115703T1 (enExample)
DK (1) DK2331547T3 (enExample)
DO (1) DOP2011000057A (enExample)
EA (1) EA019094B1 (enExample)
EC (1) ECSP11010843A (enExample)
ES (1) ES2522346T3 (enExample)
FR (1) FR17C1059I2 (enExample)
GE (1) GEP20135785B (enExample)
HN (1) HN2011000542A (enExample)
HR (1) HRP20141018T1 (enExample)
HU (1) HUS1700051I1 (enExample)
IL (1) IL211164A (enExample)
JO (1) JO2924B1 (enExample)
LT (1) LTC2331547I2 (enExample)
LU (1) LUC00048I2 (enExample)
MA (1) MA32555B1 (enExample)
ME (1) ME01282B (enExample)
MX (1) MX2011001879A (enExample)
MY (1) MY150560A (enExample)
NI (1) NI201100042A (enExample)
NL (1) NL300909I2 (enExample)
NO (1) NO2017059I1 (enExample)
NZ (1) NZ591176A (enExample)
PE (1) PE20110419A1 (enExample)
PL (1) PL2331547T3 (enExample)
PT (1) PT2331547E (enExample)
RS (1) RS53574B1 (enExample)
SI (1) SI2331547T1 (enExample)
SM (1) SMT201500017B (enExample)
TN (1) TN2011000062A1 (enExample)
TW (1) TWI468409B (enExample)
UA (1) UA103628C2 (enExample)
UY (2) UY32067A (enExample)
WO (1) WO2010020675A1 (enExample)
ZA (1) ZA201100994B (enExample)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
EP3718560A3 (en) 2009-05-13 2020-12-09 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
WO2012024500A1 (en) 2010-08-18 2012-02-23 Life Technologies Corporation Chemical coating of microwell for electrochemical detection device
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
HRP20161092T1 (hr) * 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
US9808461B2 (en) 2010-11-17 2017-11-07 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
ES2610931T3 (es) * 2011-07-01 2017-05-04 Novartis Ag Terapia de combinación
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
CA2868966C (en) * 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
CN105143463A (zh) 2013-02-25 2015-12-09 诺华股份有限公司 新的雄激素受体突变
JP2016512559A (ja) 2013-03-13 2016-04-28 アッヴィ・インコーポレイテッド Ｃｄｋ９キナーゼ阻害薬
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CA2903538A1 (en) * 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
JP2016514113A (ja) 2013-03-14 2016-05-19 アッヴィ・インコーポレイテッド ピロロ［２，３−ｂ］ピリジンｃｄｋ９キナーゼ阻害剤
UY35419A (es) 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN105407723A (zh) * 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014144596A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
PT2976106T (pt) 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
MX378263B (es) * 2013-08-14 2025-03-10 Novartis Ag Terapia de combinación para el tratamiento del cáncer.
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
AR097894A1 (es) * 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
WO2015061407A1 (en) * 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
WO2015081083A1 (en) * 2013-11-27 2015-06-04 Novartis Ag Combination therapy comprising an inhibitor of jak, cdk and pim
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
AU2014368927B2 (en) * 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
EP3086787B1 (en) * 2013-12-23 2021-01-20 Novartis AG Pharmaceutical combinations
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
HUE039504T2 (hu) * 2013-12-31 2019-01-28 Xuanzhu Pharma Co Ltd Kináz inhibitor és alkalmazása
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
DK3149008T3 (en) * 2014-05-28 2019-04-01 Shanghai Fochon Pharmaceutical Co Ltd Specific protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
IL278574B2 (en) 2014-11-12 2024-11-01 Seagen Inc Glycan-interacting compounds and methods of use
EP3231805B1 (en) * 2014-12-12 2020-03-04 Crystal Pharmatech Co. Ltd. Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
JP2018514523A (ja) 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN106146515B (zh) 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
KR102601320B1 (ko) 2015-05-29 2023-11-10 데이진 화-마 가부시키가이샤 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염
CN105037236B (zh) 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CN108348522A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 含(a)周期素依赖性激酶4/6(cdk4/6)抑制剂lee011(＝ribociclib)和(b)表皮生长因子受体(egfr)抑制剂厄洛替尼的药物组合，用于治疗或预防癌症
WO2017037587A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
EP3340991A1 (en) 2015-08-28 2018-07-04 Novartis AG Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
CN108348514A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10570141B2 (en) 2016-03-25 2020-02-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
US10865204B2 (en) 2016-04-22 2020-12-15 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
AU2017262155B2 (en) 2016-05-07 2021-03-11 Fochon Pharmaceuticals, Ltd. Certain protein kinase inhibitors
CN108290899B (zh) * 2016-06-06 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201990189A1 (ru) 2016-07-01 2019-06-28 Г1 Терапьютикс, Инк. Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20190025943A (ko) 2016-07-01 2019-03-12 쥐원 쎄라퓨틱스, 인크. 피리미딘-기재 항증식제
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
IL264950B2 (en) 2016-08-23 2024-01-01 Eisai R&D Man Co Ltd Combined treatments for the treatment of malignant liver cell carcinoma
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
BR112019005526A2 (pt) 2016-10-20 2019-06-18 Pfizer agentes antiproliferativos para tratamento de pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
AU2017359333B2 (en) 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
CN110177553A (zh) 2016-11-17 2019-08-27 北卡罗来纳大学教堂山分校 烷基吡咯并嘧啶类似物及其制备和使用方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
ES2852123T3 (es) 2016-11-28 2021-09-13 Teijin Pharma Ltd Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina y ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inhibidores de CDK4/6 para tratar p. ej. artritis reumatoide, arteriosclerosis, fibrosis pulmonar, infarto cerebral o cáncer
RS63004B1 (sr) 2016-11-28 2022-03-31 Teijin Pharma Ltd Kristal pirido[3, 4-d]pirimidin derivata ili njegov solvat
WO2018106729A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
JP2020506904A (ja) * 2017-01-27 2020-03-05 シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN110636862A (zh) 2017-03-16 2019-12-31 卫材 R&D 管理有限公司 用于治疗乳腺癌的组合疗法
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
CN110996962A (zh) 2017-08-03 2020-04-10 诺华股份有限公司 第三代egfr酪氨酸激酶抑制剂和周期素d激酶抑制剂的治疗组合
CA3073936A1 (en) 2017-08-25 2019-02-28 Sicor - Societa Italiana Corticosteroidi S.R.L. Ribociclib salts and solid state forms thereof
CN119162314A (zh) 2017-08-31 2024-12-20 诺华股份有限公司 选择针对癌症患者的治疗的方法
WO2019062854A1 (zh) * 2017-09-29 2019-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
AU2018354972B2 (en) * 2017-10-27 2021-07-08 Fresenius Kabi Oncology Ltd. An improved process for the preparation of ribociclib and its salts
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
JP2021503448A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
US11111250B2 (en) 2017-12-22 2021-09-07 Shilpa Meicare Limited Polymorphs of Ribociclib mono succinate
US11667651B2 (en) * 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US10519136B2 (en) 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3088381A1 (en) * 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3043066A1 (en) 2018-05-14 2019-11-14 Apotex Inc. Processes for the preparation of ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
IL279152B2 (en) 2018-06-05 2024-09-01 Crinetics Pharmaceuticals Inc Melanocortin subtype-2 receptor antagonists and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
AU2019338032A1 (en) * 2018-09-13 2021-05-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
WO2020140052A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
AU2020211071A1 (en) 2019-01-23 2021-07-15 Novartis Ag New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
MX2021009563A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y ribociclib.
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
TW202521536A (zh) 2019-05-05 2025-06-01 美商基尼特奇公司 Ｃｄｋ抑制劑
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP7595593B2 (ja) * 2019-06-04 2024-12-06 ステップ ファーマ エス．エー．エス 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4054583A4 (en) 2019-11-07 2023-10-25 Crinetics Pharmaceuticals, Inc. MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
DK4077307T3 (da) 2019-12-18 2025-05-26 Crinetics Pharmaceuticals Inc Gem-disubstituerede piperidinmelanocortin subtype-2-receptor- (mc2r)-antagonister og anvendelser deraf
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
WO2021133886A1 (en) 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CN114245753A (zh) * 2020-03-27 2022-03-25 江苏康宁杰瑞生物制药有限公司 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
CN113149996B (zh) * 2020-05-12 2022-12-20 苏州阿尔脉生物科技有限公司 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
EP4140997A4 (en) * 2020-05-12 2023-09-06 Suzhou Alphama Biotechnology Co., Ltd. PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
AU2021273744A1 (en) 2020-05-19 2022-12-08 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
KR20230023661A (ko) * 2020-06-11 2023-02-17 루넬라 바이오테크 인코포레이티드 선택적 cdk4/6 억제제 암 치료제
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
PE20240225A1 (es) 2020-11-24 2024-02-16 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
AU2022218128A1 (en) 2021-02-02 2023-08-17 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
US12280046B2 (en) 2021-03-19 2025-04-22 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
EP4313987A2 (en) 2021-04-01 2024-02-07 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4333847A1 (en) 2021-05-05 2024-03-13 Novartis AG Compounds and compositions for the treatment of mpnst
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
TW202320795A (zh) 2021-07-26 2023-06-01 美商凱爾科迪股份有限公司 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
KR20240041340A (ko) * 2021-07-27 2024-03-29 보로노이 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
US12275738B2 (en) 2022-04-08 2025-04-15 Biolexis Therapeutics, Inc. CDK9 inhibitors
EP4504709A1 (en) * 2022-04-08 2025-02-12 Biolexis Therapeutics, Inc. Cdk9 inhibitors
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
TWI866427B (zh) 2022-08-31 2024-12-11 美商亞文納營運公司 雌激素受體降解劑之給藥方案
EP4605088A1 (en) * 2022-10-21 2025-08-27 Novartis AG Molecular glue degrader compounds and uses thereof
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
TW202508598A (zh) 2023-05-05 2025-03-01 瑞典商阿斯特捷利康公司 癌症療法
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025080628A1 (en) * 2023-10-10 2025-04-17 Biolexis Therapeutics, Inc. Bifunctional protac and molecular glue compounds and methods of use thereof
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib
WO2025235331A1 (en) * 2024-05-07 2025-11-13 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
CN120441576B (zh) * 2025-07-08 2025-09-26 山东大学 一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
CN120483984B (zh) * 2025-07-09 2025-10-10 山东大学 一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP4291696B2 (ja) * 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
RU2301233C2 (ru) 2002-03-07 2007-06-20 Ф.Хоффманн-Ля Рош Аг Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN1878773A (zh) 2003-09-05 2006-12-13 神经能质公司 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US20070270588A1 (en) 2004-03-05 2007-11-22 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine Derivatives
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
US20070225304A1 (en) 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
CA2646429A1 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US8841312B2 (en) * 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN101981036B (zh) * 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer

Also Published As

Publication number Publication date
LTPA2017039I1 (lt) 2017-12-11
FR17C1059I1 (enExample) 2018-02-16
MA32555B1 (fr) 2011-08-01
CN103788100A (zh) 2014-05-14
EA201100355A1 (ru) 2011-10-31
AR073116A1 (es) 2010-10-13
KR101353857B1 (ko) 2014-01-21
CU20110040A7 (es) 2011-12-28
US20110152244A1 (en) 2011-06-23
TWI468409B (zh) 2015-01-11
CA2734802A1 (en) 2010-02-25
US20170183352A1 (en) 2017-06-29
CY2017042I1 (el) 2018-04-04
NZ591176A (en) 2012-11-30
TW201014858A (en) 2010-04-16
NO2017059I2 (no) 2017-11-13
BRPI0917791A2 (pt) 2019-08-13
US8962630B2 (en) 2015-02-24
ME01282B (me) 2013-06-20
WO2010020675A1 (en) 2010-02-25
DOP2011000057A (es) 2015-11-15
CA2734802C (en) 2016-05-31
UA103628C2 (en) 2013-11-11
US20240043428A1 (en) 2024-02-08
BRPI0917791B1 (pt) 2022-03-22
FR17C1059I2 (fr) 2019-01-11
US8685980B2 (en) 2014-04-01
CR20110101A (es) 2011-06-09
JP2014129361A (ja) 2014-07-10
CO6341561A2 (es) 2011-11-21
KR20110052713A (ko) 2011-05-18
HRP20141018T1 (hr) 2015-02-13
IL211164A (en) 2016-09-29
MX2011001879A (es) 2011-03-29
RS53574B1 (sr) 2015-02-27
EP2331547A1 (en) 2011-06-15
NL300909I1 (enExample) 2017-11-10
EA201100355A8 (ru) 2013-09-30
US20210253578A1 (en) 2021-08-19
ES2522346T3 (es) 2014-11-14
CN102186856B (zh) 2014-09-24
NO2017059I1 (no) 2017-11-13
PL2331547T3 (pl) 2015-01-30
UY32067A (es) 2010-03-26
JO2924B1 (en) 2015-09-15
KR20130140222A (ko) 2013-12-23
EP2331547B1 (en) 2014-07-30
JP5560496B2 (ja) 2014-07-30
CY1115703T1 (el) 2017-01-25
AU2009284098B2 (en) 2012-03-29
IL211164A0 (en) 2011-04-28
LUC00048I1 (enExample) 2017-11-15
US20130184285A1 (en) 2013-07-18
EA019094B1 (ru) 2014-01-30
EP2716643A1 (en) 2014-04-09
SI2331547T1 (sl) 2014-11-28
ECSP11010843A (es) 2011-05-31
NI201100042A (es) 2011-08-09
CL2011000306A1 (es) 2011-06-24
LUC00048I2 (enExample) 2018-01-10
JP5882371B2 (ja) 2016-03-09
GEP20135785B (en) 2013-03-11
LTC2331547I2 (lt) 2018-09-10
US20100105653A1 (en) 2010-04-29
JP2012500785A (ja) 2012-01-12
AR111763A2 (es) 2019-08-14
DK2331547T3 (da) 2014-11-03
US20180155351A1 (en) 2018-06-07
SMT201500017B (it) 2015-03-05
NL300909I2 (nl) 2017-12-19
UY38935A (es) 2020-12-31
US8415355B2 (en) 2013-04-09
CN102186856A (zh) 2011-09-14
HUS1700051I1 (hu) 2017-12-28
HK1156625A1 (en) 2012-06-15
PE20110419A1 (es) 2011-07-13
PT2331547E (pt) 2014-10-29
TN2011000062A1 (en) 2012-09-05
CY2017042I2 (el) 2018-04-04
AU2009284098A1 (en) 2010-02-25
MY150560A (en) 2014-01-30
US9416136B2 (en) 2016-08-16
CU24062B1 (es) 2014-12-26
CA2734802E (en) 2010-02-25
US20140135312A1 (en) 2014-05-15
ZA201100994B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
HN2011000542A (es) Compuestos de pirrolo- pirimidina como inhibidores de cdk
EA200900799A1 (ru) Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112014030424A2 (pt) formas cristalinas de um inibidor de quinase de tirosina de bruton
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
GT201200167A (es) Compuestos triciclicos novedosos
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
PH12015502053A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
ECSP10010716A (es) Combinaciones farmaceuticas.
Wang et al. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition
WO2022236255A3 (en) Heterocyclic compounds as kinase inhibitors
Patti et al. Improvement of quality of life in elderly after inguinal hernioplasty
AR098210A1 (es) Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias
HN2001000078A (es) Compuestos, composiciones farmaceuticas y metodos para inhibir kinasas proteinicas solicitante:agouron pharmaceuticals, inc. pais: estados unidos de america.